Company Encyclopedia
View More
name
IGC Pharma
IGC.US
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc.
4.514 T
IGC.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking151/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-83.34%E
    • Profit Margin-582.82%E
    • Gross Margin51.83%B
  • Growth ScoreC
    • Revenue YoY-6.51%D
    • Net Profit YoY48.72%B
    • Total Assets YoY-6.04%D
    • Net Assets YoY9.69%B
  • Cash ScoreD
    • Cash Flow Margin-17.16%D
    • OCF YoY-6.51%D
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreA
    • Gearing Ratio16.95%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

    IGC Pharma has published a caregiver-focused book, "Caring for a Loved One with Alzheimer's Disease," authored by experts in neuropsychology and dementia care. The book provides educational content and real-life caregiver stories, reinforcing IGC Pharma's leadership in Alzheimer's innovation. It aligns with the company's mission to address Alzheimer's from scientific, social, and therapeutic angles, supporting community awareness and strategic positioning in therapeutic innovation.

    Acceswire·
    US
    IGC
    +1.36%
    Acceswire·
    US
    IGC
    +1.36%

    IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

    IGC Pharma announced advances in MINT-AD, an AI-driven initiative to identify socioeconomic risk factors influencing Alzheimer's and aging trends. Utilizing data from global longitudinal studies, the project aims to predict, stratify, and intervene in cognitive decline. The initiative supports IGC's mission to revolutionize Alzheimer's treatment with precision medicine and complements ongoing clinical trials. The project focuses on risk stratification, early detection, and modeling disease progression under different interventions, aiming to transform public health policies and improve clinical outcomes.

    Acceswire·
    US
    IGC
    +1.36%
    Acceswire·
    US
    IGC
    +1.36%

    IGC Pharma Reports Progress Amid Financial Losses

    IGC Pharma reported a Q2 net loss of $1.8 million with revenues of $191,000, a decrease from the previous year. Despite financial losses, the company made progress in clinical trials, enrolling over 50% of patients in its Phase 2 study for IGC-AD1. IGC is advancing its AI platform for drug discovery and trial design, focusing on Alzheimer's therapies to create value for patients and shareholders.

    Tip Ranks·
    US
    IGC
    +1.36%
    Tip Ranks·
    US
    IGC
    +1.36%

    IGC Pharma Sells Non-Core Facility for $2.7 Million

    IGC Pharma Inc. has sold a non-core manufacturing facility for $2.7 million, resulting in a non-cash profit of $1.1 million and reducing annual operating expenses by $600,000. The deal also provides long-term preferential supply rights, enhancing financial flexibility. This strategic divestiture was announced on November 17, 2025, and aims to improve the company's financial position.

    Reuters·
    US
    IGC
    +1.36%
    Reuters·
    US
    IGC
    +1.36%

    IGC Pharma | 10-Q: FY2026 Q2 Revenue Misses Estimate at USD 191 K

    LB filings·
    US
    IGC
    +1.36%
    LB filings·
    US
    IGC
    +1.36%
    © 2025 Longbridge｜Disclaimer